OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Brohl on the Safety and Efficacy of IFx-Hu2.0 in MCC and CSCC

July 5th 2023

Andrew S. Brohl, MD, discusses the safety and immunologic responses with intratumoral administration of Idx-Hu2.0 in patients with advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Dr Schrag on Neoadjuvant Chemotherapy and Selective Chemoradiation in Locally Advanced Rectal Cancer

July 5th 2023

Deb Schrag, MD, MPH, discusses findings from the phase 2/3 PROSPECT trial in patients with rectal cancer.

Dr DePalo on First-Line Therapies in Unresectable Melanoma In-Transit Metastases

July 5th 2023

Danielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.

Dr Santin on the Clinical Activity of Sacituzumab Govitecan in Recurrent Endometrial Cancer

June 30th 2023

Alessandro Santin, MD, discusses the clinical activity of sacituzumab govitecan-hziy in patients with recurrent endometrial cancer who overexpress Trop-2.

Dr Saltos on Pembrolizumab Plus Vorinostat in mNSCLC

June 30th 2023

Andreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.

Dr Sun on the Association of Duration of Immunotherapy and OS in NSCLC

June 30th 2023

Lova L. Sun, MD, MSCE, discusses the association between duration of immunotherapy and overall survival in patients with advanced non–small-cell lung cancer.

Dr Spira on the Ongoing PACIFIC-8 Trial in Unresectable Stage III NSCLC

June 30th 2023

Alexander I. Spira, MD, PhD, FACP, discusses the ongoing phase 3 PACIFIC-8 trial of durvalumab in combination with domvanalimab following concurrent chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer.

Dr Sasine on the Potential Use of Cilta-Cel in Earlier Lines for Multiple Myeloma

June 30th 2023

Joshua P. Sasine, MD, PhD, discusses the potential role of cilta-cel in earlier lines of therapy for patients with multiple myeloma.

Dr Oveisi on the Potential Role of Bispecific Antibodies in Multiple Myeloma

June 30th 2023

David R. Oveisi, MD, discusses the evolution and potential role of bispecific antibodies in multiple myeloma, and presents several areas of unmet need regarding their use in this space.

Dr O’Brien on the Use of Pirtobrutinib in BTK Inhibitor-Resistant MCL and CLL

June 30th 2023

Susan M. O’Brien, MD, discusses the use of pirtobrutinib for patients with hematologic malignancies who developed resistance to BTK inhibition.

Dr Schinke on Talquetamab in Multiple Myeloma

June 30th 2023

Carolina D. Schinke, MD, discusses updated findings from the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Dr Vaishampayan on Cabozantinib Plus Atezolizumab in RCC

June 29th 2023

Ulka Nitin Vaishampayan, MBBS, discusses findings from the phase 3 CONTACT-03 trial in patients with renal cell carcinoma.

Dr Monk on Avutometinib Plus Defactinib in Low-Grade Serous Ovarian Cancer

June 29th 2023

Bradley Monk, MD, FACS, FACOG, discusses findings from the phase 2 RAMP 201 trial in patients with low-grade serous ovarian cancer and the importance of these results within the context of the larger ovarian cancer treatment paradigm.

Dr Yang on the Results of the KEYNOTE-789 Trial in EGFR-mutant NSCLC

June 29th 2023

James Chih-Hsin Yang, MD, discusses the investigation of pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous non–small cell lung cancer.

Dr Sonpavde on the Potential Impact of the THOR Study in FGFR2/3-Altered Urothelial Carcinoma

June 29th 2023

Guru P. Sonpavde, MD, discusses the potential impact of the phase 3 THOR study evaluating erdafitinib vs chemotherapy in patients with advanced or metastatic urothelial cancer harboring FGFR2/3 alterations.

Dr Pellini on the Use of ctDNA Monitoring After Chemoimmunotherapy Induction in NSCLC

June 29th 2023

Bruna Pellini, MD, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced non–small cell lung cancer treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel.

Dr Huang on the Use of Neoadjuvant PARP Inhibitors in Advanced Ovarian Cancer

June 29th 2023

Marilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.

Dr Coopey on the Benefits of Axillary Surgery Omission or De-Escalation in Breast Cancer

June 29th 2023

Suzanne B. Coopey, MD, FACS, discusses the benefits seen with the de-escalation of axillary lymph node surgery for patients with breast cancer, as well as current recommendations for the de-escalation or omission of this procedure.

Dr Lam on the Tumor Microenvironment in ALK Fusion+ Lung Cancer

June 29th 2023

Vincent K. Lam, MD, discusses findings from a study profiling the tumor immune microenvironment in patients with ALK fusion–positive lung cancer and potential future directions for this research.

Dr Pant on the Background of the RAGNAR Trial in FGFR-altered Solid Tumors

June 28th 2023

Shubham Pant, MD, MBBS, discusses the background of the ongoing phase 2 RAGNAR trial evaluating the use of erdafitinib in patients with solid tumors harboring FGFR alterations.